If you have been reading about melanocortin analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-04-23. Where a claim depends on a specific study, the study is described rather than over-claimed.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
The compound emerged from a research programme examining melanocortin analogues for effects on skin pigmentation. During early human studies, participants reported spontaneous erections as an unexpected side effect, which redirected development toward sexual function rather than tanning. An intranasal formulation was investigated in clinical trials but did not reach market approval. A subcutaneous injectable version later completed the regulatory process, and the nasal route does not appear in approved labelling.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Bremelanotide acts as an agonist at several melanocortin receptors, with the strongest reported activity at MC4R and measurable activity at MC1R and MC3R. Because MC4R is expressed in hypothalamic and limbic circuits, the proposed mechanism links receptor activation to modulation of central pathways involved in desire rather than to direct effects on peripheral genital tissue. The precise downstream steps remain incompletely characterized, and evidence for the involvement of specific neurotransmitters is suggestive rather than settled. Nausea and blood pressure elevation reported during trials are consistent with melanocortin signaling outside the intended target circuit.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
=== Genetic testing === Variations of the HLA-B gene increase the risk of developing ankylosing spondylitis, although it is not a diagnostic test. Those with the HLA-B27 variant are at a higher risk than the general population of developing the disorder, yet most individuals with the genetic marker do not develop AS. Thus, HLA-B27, demonstrated in a blood test, can help with diagnosis, but in itself is not diagnostic of AS in a person with back pain. Over 85% of people that have been diagnosed with AS are HLA-B27 positive, although this ratio varies from population to population: about 50% of African Americans with AS possess HLA-B27 in contrast to the figure of 80% among those with AS who are of Mediterranean descent. In Turkey, a study of 115 patients found 70% positivity for the HLA-B27 allele.
Some women feel discomfort when breastfeeding in public. Public breastfeeding may be forbidden in some places, not addressed by law in others, and a legal right in others. Even given a legal right, some mothers are reluctant to breastfeed, while others may object to the practice. It is estimated that around 63% of mothers worldwide have publicly breastfed. The media have reported several incidents in which workers or members of the public have objected to or forbidden women breastfeeding. Some mothers avoid the negative attention and choose to move to another location. But some mothers have protested their treatment and have taken legal action or engaged in protests. Protests have included a public boycott of the offender's business, organizing a "nurse-in" or a breastfeeding flash mob, in which groups of nursing mothers gather at the location where the complaint originated and nursed their babies at the same time. In response, some companies have apologised and instituted reforms. The use of infant formula was thought to be a way for Western culture to adapt to negative perceptions of breastfeeding. The breast pump offered a way for mothers to supply breast milk with most of formula feeding's convenience and without enduring possible disapproval of nursing. Some may object to breastfeeding because of the implicit association between infant feeding and sex. These negative cultural connotations may reduce breastfeeding duration. Maternal guilt and shame are often affected by how a mother feeds an infant.
=== Admission to hospital === Patients with AN may be deemed to have a lack of insight regarding the necessity of treatment, and thus may be involuntarily treated without their consent. AN has a high mortality and patients admitted in a severely ill state to medical units are at particularly high risk. Diagnosis can be challenging, risk assessment may not be performed accurately, consent and the need for compulsion may not be assessed appropriately, refeeding syndrome may be missed or poorly treated and the behavioural and family problems in AN may be missed or poorly managed. Guidelines published by the Royal College of Psychiatrists recommend that medical and psychiatric experts work together in managing severely ill people with AN.
== Early political career == He transitioned into politics in 1977, when he served one term on the East Hartford Board of Education. He then served two terms on the East Hartford Town Council. In 1982, Larson was elected to the Connecticut State Senate from the 3rd district, based in East Hartford. He served six terms in that body, the last four as president pro tempore. In 1994, Larson left the state senate and sought the Democratic nomination for governor of Connecticut, losing to Bill Curry in the primary. After being defeated for governor, Larson entered private business for several years but was able to maintain his political credentials.
Sources: en.wikipedia.org
Translation moves the tRNA from the A-site through the P- and E-sites, with the exception of the initiator tRNA, which binds directly to the P-site. Recent experiments have reported that protein translation can also initiate from the A-site. Using toeprinting assay, it has been shown that protein synthesis initiates from the A-site of the ribosome (eukaryotic) in the cricket paralysis virus (CrPV). IGR-IRES (intragenic regions-internal ribosome entry sites) can assemble 80S ribosomes from 40S and 60S ribosomal subunits in the absence of eIF2, Met-tRNAi, or GTP hydrolysis and without a coding triplet in the ribosomal P-site. Authors also showed IGR-IRES can direct translation of a protein whose N-terminal residue is not methionine.
In 2021, Lloyd Austin, on behalf of the United States, thanked his counterpart in the Philippines Delfin Lorenzana for retaining the 70-year-old visiting forces agreement between the two nations. In 2023, four new bases were announced in the Philippines.
== Logistics == In the World Bank's Logistics Performance Index (LPI) 2018 Thailand ranked 32 of 160 nations (1=best, 160=worst). Other ASEAN nations were ranked: Singapore, 7; Vietnam, 39; Malaysia, 41; Indonesia, 46; Philippines, 60; Brunei, 80; Laos, 82, Cambodia, 98 and Myanmar, 137.
Many vulture species are obligately necrophagous including the bearded vulture, black vulture, cinereous vulture, Eurasian griffon, Himalayan vulture, king vulture and turkey vulture. Types of carrion fed upon include dead wildlife, livestock, poultry and companion animals, human remains (sky burial), hunting discards, slaughterhouse offal and roadkill. Typically, muscle tissue is consumed, but bearded vultures feed on bones and bone marrow. In addition to eating carrion, Egyptian vultures feed on small live animals such as turtles, eggs and rotting fruit. Vultures have many adaptations that help them detect, locate and consume carrion. For example, all vultures have keen eyesight, and New World vultures have a highly developed sense of smell. Hooded vultures also have excellent auditory perception, enabling them to hear distant predation-related noises and the distress calls of dying animals. In addition, gliding flight enables vultures to cover long distances to reach carrion, strong beaks allow vultures to cut through thick animal skin, and strong immune defenses protect vultures from pathogens in carrion. Given the inherently unpredictable and ephemeral nature of carrion as a food source, the ability of vultures to survive long periods between meals is also advantageous. Some human activities have had an adverse impact on vultures in Sicily, the Azerbaijan Republic and other countries.
=== SARM1 === SARM1 is a Toll-like receptor protein and also functions as a intracellular NADase. Under normal circumstances NADase activity are inhibited in the presence of NAD+, where NAD+ binds to armadillo/heat motifs (ARMs), which inhibits the dimerization of the toll-like receptor domain that activates the NADase activity. If there are damages to the binding site of NAD+ or disruption that prevents the interaction between ARMs and the toll-like receptor domain, NADase activity will be turned on at a constitutive level. As a result SARM1 will have higher consumption of NAD+ and produce NADase products (ADP-ribose and nicotinamide) rather than the production of cADPR from ADP-ribosyl cyclase.
Sources: en.wikipedia.org
== Strep-tag applications == The Strep-tag system offers a selective tool to purify proteins under physiological conditions. The proteins obtained are bioactive and display a very high purity (above 95%). Also, the Strep-tag system can be used for protein detection in various assays. Depending on the experimental circumstances, Strep-tag antibodies or Strep-Tactin, with an enzymatic (e.g.horseradish peroxidase (HRP), alkaline phosphatase (AP)) or fluorescence (e.g. green fluorescent protein (GFP)) marker. If high purity is required, the lysate can be purified by first using Strep-Tactin and then perform a second run using antibodies against Strep-tag. This reduces the contamination with unspecific bound proteins, which might occur in some rare scenarios. Following assays can be conducted using the Strep-tag detection system:
Since iron is primarily required for hemoglobin, iron deficiency anemia is the primary clinical manifestation of iron deficiency. Iron-deficient people will suffer or die from organ damage well before their cells run out of the iron needed for intracellular processes like electron transport. Macrophages of the reticuloendothelial system store iron as part of the process of breaking down and processing hemoglobin from engulfed red blood cells. Iron is also stored as a pigment called hemosiderin, which is an ill-defined deposit of protein and iron, created by macrophages where excess iron is present, either locally or systemically, e.g., among people with iron overload due to frequent blood cell destruction and the necessary transfusions their condition calls for. If systemic iron overload is corrected, over time the hemosiderin is slowly resorbed by the macrophages.
The deportees were released on 19 December and allowed to travel to Cairo and then, with Jamal Husseini, to Beirut where a new Arab Higher Committee (or Higher National Committee) was established. Amin al-Husayni was not a member of the Arab delegation but the delegation was clearly acting under his direction. The London Conference commenced on 7 February 1939, but the Arab delegation refused to sit in the same room with the Jewish delegation present, and the conference broke up in March with no success. In May 1939, the British government presented its 1939 White Paper which was rejected by both sides. The White Paper had, in effect, repudiated the Balfour Declaration. According to Benny Morris, Amin al-Husayni "astonished" the other members of the Arab Higher Committee by turning down the White Paper. Al-Husayni turned the advantageous proposal down because "it did not place him at the helm of the future Palestinian state." The deportees were not allowed to return to Palestine until 1941. Amin Al-Husayni spent the war years in occupied Europe, actively collaborating with the Nazi leadership. Amin and Jamal al-Husayni were involved in the 1941 pro-Nazi Rashidi revolt in Iraq. Amin again evaded capture by Britain but Jamal was captured in 1941 and interned in Southern Rhodesia, where he was held until November 1945 when he was allowed to move to Cairo. Husayn al-Khalidi returned to Palestine in 1943. Jamal al-Husayni returned to British Palestine in February 1946 as an official of the new Arab Higher Committee, by then recognised by the Mandate administration.
Corals predominantly reproduce sexually. About 25% of hermatypic corals (reef-building stony corals) form single-sex (gonochoristic) colonies, while the rest are hermaphroditic. It is estimated more than 67% of coral are simultaneous hermaphrodites.
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.